← Back
$APLS All transactions

Apellis Pharmaceuticals, Inc.

A

$ Value

$0

Shares

92,592

Price

$0

Filed

Sep 2

Insider

Name

MELTZER LESLIE

Title

Chief Research and Development

CIK

0002084030

Roles

Officer

Transaction Details

Transaction Date

2025-08-26

Code

A

Table

Derivative

Ownership

Direct

Equity Swap

No

Shares After

92,592

Footnotes

This restricted stock unit was granted on August 26, 2025. The restricted stock unit will vest 25% annually over four years from grant date, subject to her continued service as an officer, or upon later termination of her service. | This represents a stock option award granted August 26, 2025 that vests over a four-year period. 25% vests one year from grant date and the remaining 75% vests monthly thereafter subject to continued service.

Filing Info

Accession No.

0001127602-25-021056

Form Type

4

Issuer CIK

0001492422

MELTZER LESLIE's History

Date Ticker Type Value
2026-01-28 APLS A $0
2025-08-26 APLS A $0
2025-08-26 APLS A $0

Other Insiders at APLS (90d)

Insider Bought Sold Last
Dolsten Mikael 2026-02-27
Watson David O.
General Counsel
2026-01-28
Deschatelets Pascal
Chief Scientific Officer
2026-01-28
Francois Cedric
Chief Executive Officer
2026-03-11
Sullivan Timothy Eugene
Chief Financial Officer
2026-04-17
O'Brien Stephanie Monaghan 2026-04-06
Nicholson Nur
Chief Technical Officer
2026-01-28
Chopas James George
VP/Chief Accounting Officer
2026-01-28
DeLong Mark Jeffrey
Chief Business & Strat Officer
$8K 2026-02-11
Boucher Kelley
Chief People Officer
2026-01-28
MELTZER LESLIE
Chief Research and Development
2026-01-28